Clinical Proteomics

Scope & Guideline

Unveiling the Power of Proteins in Health and Disease

Introduction

Delve into the academic richness of Clinical Proteomics with our guidelines, detailing its aims and scope. Our resource identifies emerging and trending topics paving the way for new academic progress. We also provide insights into declining or waning topics, helping you stay informed about changing research landscapes. Evaluate highly cited topics and recent publications within these guidelines to align your work with influential scholarly trends.
LanguageEnglish
ISSN1542-6416
PublisherBMC
Support Open AccessYes
CountryUnited Kingdom
TypeJournal
Converge2004, from 2006 to 2024
AbbreviationCLIN PROTEOM / Clin. Proteom.
Frequency1 issue/year
Time To First Decision-
Time To Acceptance-
Acceptance Rate-
Home Page-
AddressCAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND

Aims and Scopes

The journal 'Clinical Proteomics' is dedicated to advancing the field of clinical proteomics, emphasizing the application of proteomic technologies in understanding disease mechanisms, identifying biomarkers, and improving patient outcomes. It covers a broad spectrum of research involving proteomic analyses across various clinical scenarios.
  1. Clinical Applications of Proteomics:
    The journal focuses on the application of proteomic technologies to discover and validate biomarkers for disease diagnosis, prognosis, and therapeutic monitoring across a variety of conditions, including cancer, cardiovascular diseases, and autoimmune disorders.
  2. Innovative Methodologies:
    It emphasizes the development and application of innovative proteomic methodologies, such as mass spectrometry and data-independent acquisition techniques, which enhance the sensitivity and specificity of protein analysis in clinical samples.
  3. Interdisciplinary Research:
    The journal encourages interdisciplinary research that combines proteomics with other omics technologies (genomics, transcriptomics, and metabolomics) to provide a comprehensive understanding of disease biology and facilitate personalized medicine.
  4. Biomarker Discovery and Validation:
    A significant focus is on the discovery and validation of novel protein biomarkers that can aid in the early detection of diseases, monitor disease progression, and predict treatment responses.
  5. Patient-Centric Studies:
    Clinical Proteomics often publishes studies that directly involve patient samples, reflecting real-world clinical scenarios to ensure that findings are applicable and beneficial to patient care.
The journal has seen a rise in interest in several emerging themes, reflecting the evolving landscape of clinical proteomics and the increasing integration of technological advancements in research.
  1. Proteomics in Cancer Research:
    There is a notable trend in the application of proteomics to cancer research, particularly in understanding tumor heterogeneity, resistance mechanisms, and the identification of novel biomarkers for early detection and targeted therapy.
  2. Integration of Multi-Omics Approaches:
    Emerging studies are increasingly integrating proteomics with genomics and metabolomics, allowing for a more comprehensive understanding of biological systems and disease mechanisms, enhancing predictive modeling and personalized medicine.
  3. Machine Learning and Bioinformatics in Proteomics:
    The utilization of machine learning and advanced bioinformatics tools to analyze complex proteomic datasets is growing, enabling researchers to uncover patterns that can lead to new insights in disease pathology and treatment responses.
  4. Non-Invasive Biomarker Discovery:
    There is a heightened focus on non-invasive proteomic biomarkers derived from bodily fluids (e.g., saliva, urine), which are crucial for developing diagnostic tools that are easier to implement in clinical settings.
  5. COVID-19 Related Proteomics:
    The ongoing research related to COVID-19 has led to a surge in publications that explore the proteomic landscape of the virus and its effects on the human body, highlighting the importance of proteomics in understanding infectious diseases.

Declining or Waning

While 'Clinical Proteomics' continues to expand in several areas, certain themes have shown a decline in frequency or prominence in recent publications. These waning scopes may reflect shifts in research priorities or advancements in technology that have rendered some topics less relevant.
  1. Basic Research without Clinical Relevance:
    Research focusing solely on basic proteomic techniques without direct application to clinical issues has decreased, as there is a growing preference for studies that link proteomics directly to clinical outcomes.
  2. Single Omics Studies:
    There has been a decline in publications that focus exclusively on proteomics without integrating other omics approaches, as the trend shifts towards more holistic, multi-omics strategies that provide a more comprehensive view of disease.
  3. Traditional Biomarker Approaches:
    The reliance on traditional biomarker discovery approaches, which often do not incorporate advanced proteomic technologies, has waned in favor of more innovative and sophisticated methodologies that offer greater sensitivity and specificity.
  4. Non-Quantitative Proteomics Studies:
    The frequency of studies employing qualitative proteomic analyses has decreased, as the field increasingly values quantitative approaches that provide measurable and reproducible results.

Similar Journals

Biomedical Reports

Exploring the frontiers of biochemistry and genetics.
Publisher: SPANDIDOS PUBL LTDISSN: 2049-9434Frequency: 6 issues/year

Biomedical Reports, published by SPANDIDOS PUBL LTD in Greece, is a distinguished open-access journal that focuses on the dynamic fields of biochemistry, genetics, molecular biology, medicine, pharmacology, and neuroscience. Established in 2014, the journal has rapidly gained recognition, securing Q2 and Q3 rankings in several categories for 2023, including a notable ranking of #125/636 in General Medicine, placing it in the 80th percentile amongst its peers. The journal continually aims to disseminate innovative research findings that advance the understanding of complex biomedical issues, making it an invaluable resource for researchers, professionals, and students alike. Its multidisciplinary approach not only reflects the interconnectivity of modern biomedical sciences but also promotes collaborative discourse among diverse fields, ensuring ongoing relevance and impact within the scientific community.

Cancer Informatics

Bridging the Gap Between Data and Cancer Solutions
Publisher: SAGE PUBLICATIONS LTDISSN: Frequency: 1 issue/year

Cancer Informatics, published by SAGE PUBLICATIONS LTD, is a leading open-access journal dedicated to the integration of computational techniques and cancer research. Since its inception in 2005, this journal has become a vital resource for researchers, professionals, and students interested in the intersection of informatics and oncology. With an E-ISSN of 1176-9351 and a focus on the innovative application of data analysis in cancer research, Cancer Informatics serves to disseminate critical findings that aid in understanding cancer biology and enhancing treatment modalities. Recognized in the Q3 category for both Cancer Research and Oncology according to the 2023 metrics, it currently holds a Scopus ranking of #246 in Medicine _ Oncology and #172 in Biochemistry, Genetics and Molecular Biology _ Cancer Research, indicating its contribution to ongoing research in these fields. This journal not only supports open access to scientific findings but also aims to foster collaboration among interdisciplinary scholars worldwide, making it an essential platform for advancing the field of cancer informatics through cutting-edge research and innovative methodologies.

CLINICAL AND EXPERIMENTAL IMMUNOLOGY

Exploring Innovative Insights in Clinical Immunology
Publisher: OXFORD UNIV PRESSISSN: 0009-9104Frequency: 12 issues/year

Clinical and Experimental Immunology, published by Oxford University Press, is a premier journal that has been a cornerstone in the field of immunology since its inception in 1966. With an ISSN of 0009-9104 and an E-ISSN of 1365-2249, this journal holds a significant position in academic research, currently ranking in the Q2 category for both Immunology and Allergy (2023). Its impactful contributions are reflected in its Scopus rankings, where it stands at Rank #63 out of 233 in Immunology and Allergy, placing it in the 73rd percentile, and Rank #73 out of 236 in Immunology and Microbiology. Researchers, healthcare professionals, and students will find this journal an invaluable resource for cutting-edge studies, reviews, and clinical advancements in the ever-evolving domain of immunology. While the publication does not offer open-access options, it remains a pivotal platform for disseminating knowledge that impacts both clinical practice and experimental research.

EUROPEAN JOURNAL OF MASS SPECTROMETRY

Unlocking Molecular Mysteries, One Spectrum at a Time
Publisher: SAGE PUBLICATIONS LTDISSN: 1469-0667Frequency: 6 issues/year

European Journal of Mass Spectrometry, published by SAGE Publications Ltd, is a premier academic journal dedicated to advancing the field of mass spectrometry and its applications in atomic, molecular physics, and medical sciences. With an ISSN of 1469-0667 and an E-ISSN of 1751-6838, this journal serves as a vital platform for disseminating innovative research findings and methodologies that enhance our understanding of complex molecular structures and interactions. Operating from the United Kingdom, it has established itself within the academia by achieving a Q3 ranking in several categories, including Atomic and Molecular Physics and Spectroscopy, as per the 2023 category quartiles. Researchers and professionals can access a diverse range of articles that not only address theoretical aspects but also practical applications in various scientific disciplines. As the field continues to evolve, the European Journal of Mass Spectrometry plays a crucial role in fostering collaboration and knowledge sharing among experts, making it an indispensable resource for anyone invested in mass spectrometry and its interdisciplinary connections.

RAPID COMMUNICATIONS IN MASS SPECTROMETRY

Transforming research into practical applications.
Publisher: WILEYISSN: 0951-4198Frequency: 24 issues/year

RAPID COMMUNICATIONS IN MASS SPECTROMETRY is a leading journal published by Wiley, focusing on the rapidly evolving field of mass spectrometry and its applications across various domains, including analytical, organic, and spectroscopy chemistry. With its ISSN 0951-4198 and an E-ISSN of 1097-0231, the journal has firmly established itself as a reputable source of innovative research since its inception in 1987, and is set to continue until 2024. As evidenced by its 2023 Scopus rankings, the journal occupies a solid position in the realms of analytical chemistry (Q3), organic chemistry (Q3), and spectroscopy (Q3), reflecting its impact among a diverse audience of researchers and professionals. Although it is not an open-access publication, the findings shared within its pages are pivotal for advancing knowledge and practical applications in mass spectrometry, making it an essential resource for students and experts aiming to stay abreast of the latest scientific developments.

Translational Cancer Research

Catalyzing progress in oncology and imaging sciences.
Publisher: AME PUBLISHING COMPANYISSN: 2218-676XFrequency: 12 issues/year

Translational Cancer Research, published by AME Publishing Company in Hong Kong, is a pivotal journal aimed at fostering the advancement of oncology-related knowledge through the dissemination of high-quality research findings. With its ISSN 2218-676X and E-ISSN 2219-6803, this journal serves as a vital resource for researchers, professionals, and students in the fields of Cancer Research, Oncology, and Radiology, Nuclear Medicine, and Imaging. Established in 2012, the journal covers the latest breakthroughs and cross-disciplinary approaches that drive innovation in cancer treatment and diagnostics. Although currently classified in the Q4 Quartile for Cancer Research and Q3 for both Oncology and Radiology, Translational Cancer Research continuously works toward improving its academic influence and impact, evidenced by its ongoing research contributions. The journal emphasizes open access, making crucial research available to a global audience. We invite scholars and industry professionals to engage with the latest findings and discussions within these critical areas of medical science.

Proteomes

Championing Open Access to Cutting-Edge Proteomic Research.
Publisher: MDPIISSN: Frequency: 4 issues/year

Proteomes, published by MDPI since 2013, is a notable open access journal that occupies a critical place in the realms of Biochemistry, Clinical Biochemistry, Molecular Biology, and Structural Biology. Based in Switzerland, this journal not only promotes the dissemination of high-quality research pertaining to protein structures and functions but also emphasizes interdisciplinary approaches that bridge various fields of biomedical science. With a Category Quartile ranking of Q2 across multiple pertinent categories in 2023, Proteomes boasts a competitive impact within the scientific community, evidenced by its robust Scopus rankings. Researchers, professionals, and students are invited to explore a wealth of pioneering studies and reviews that are made freely accessible, aligning with global trends in open scientific communication. Whether contributing original research or seeking to expand their knowledge, the journal serves as an invaluable resource for anyone engaged in the evolving landscape of proteomics.

Physiology and Pharmacology

Empowering researchers through open access knowledge.
Publisher: IRANIAN SOC PHYSIOLOGY & PHARMACOLOGYISSN: 2476-5236Frequency: 4 issues/year

Physiology and Pharmacology is a distinguished open access journal that has been disseminating high-quality research in the fields of physiology and pharmacology since its inception in 1997. Published by the Iranian Society of Physiology & Pharmacology, this journal offers a platform for scholars and practitioners to share innovative findings and advancements that contribute to the understanding of biological systems and drug action. With its ISSN 2476-5236 and E-ISSN 2476-5244, it ensures global reach and accessibility. The journal is positioned in the third quartile for Linguistics and Language and fourth quartile in both Pharmacology and Physiology categories according to Scopus rankings, reflecting a commitment to expanding knowledge within these interdisciplinary domains. Set within the academic landscape of Iran, the journal aims to bridge regional research with the international community, providing valuable insights into physiological processes and pharmacological developments. In light of its open access model, the Physiology and Pharmacology journal plays a crucial role in enhancing the visibility of research outcomes and fostering collaboration among researchers, professionals, and students on a global scale.

Genome Medicine

Connecting Genetics to Clinical Excellence
Publisher: BMCISSN: 1756-994XFrequency: 1 issue/year

Genome Medicine is a prestigious, peer-reviewed journal published by BMC, focusing on the rapidly evolving fields of genetics, molecular biology, and molecular medicine. Established in 2009 and boasting an open-access format, it has become a leading platform for disseminating high-quality research findings that advance our understanding of genetic diseases and therapeutic innovations. With an impressive Q1 ranking across multiple relevant categories—in particular, genetics (clinical), molecular biology, and molecular medicine—this journal is recognized for its substantial impact in the academic community, as evidenced by its exceptional placement in Scopus rankings. By providing unrestricted access to groundbreaking studies, Genome Medicine fosters collaboration and knowledge sharing among researchers, clinicians, and educators, thus playing a vital role in the transition from fundamental genetic research to clinical applications. Researchers are encouraged to contribute their findings and insights, further solidifying the journal’s position as a pivotal resource for those dedicated to advancing genomic medicine.

Biomarker Research

Connecting global minds to elevate biomarker science.
Publisher: BMCISSN: Frequency: 1 issue/year

Biomarker Research is a leading open access journal published by BMC, dedicated to advancing the field of biomarker discovery and clinical application. Since its inception in 2013, this journal has become a crucial resource for researchers and professionals in biochemistry, clinical biochemistry, and molecular medicine, achieving a prestigious Q1 ranking in each category in 2023. With an E-ISSN of 2050-7771, it maintains a strong reputation for disseminating high-quality research and innovative findings that contribute to the understanding of disease mechanisms and the development of novel diagnostics and therapeutics. The journal is accessible to a global audience, ensuring that vital research is freely available to promote collaboration and accelerate scientific progress. Operating out of the United Kingdom, Biomarker Research plays a significant role in addressing some of the most pressing challenges in medical research, making it an essential resource for academics, clinicians, and industry professionals alike.